预约演示
更新于：2026-02-27
Voriconazole
伏立康唑
更新于：2026-02-27
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C16H14F3N5O |
InChIKeyBCEHBSKCWLPMDN-MGPLVRAMSA-N |
CAS号137234-62-9 |
关联
268
项与 伏立康唑 相关的临床试验NCT07426042
A Clinical Study Evaluating the Effects of Dexamethasone on the Activities of CYP2C9, CYP2C19, and CYP3A4 Substrates in Healthy Male Subjects
Purpose:
The purpose of this study is to understand how dexamethasone affects the activity of drug-metabolizing enzymes in the body and how this may influence interactions with other medicines, such as voriconazole.
Background:
Many medicines are broken down in the body by enzymes called cytochrome P450 (CYP) enzymes. Differences in CYP enzyme activity between individuals can lead to variability in drug response and drug-drug interactions. Dexamethasone is known to affect CYP enzyme activity, and voriconazole is a medication that is metabolized by these enzymes.
Participants:
This study will include a total of 12 healthy adult male volunteers. Participants will be grouped based on their metabolic status, including 6 normal metabolizers (NM) and 6 poor metabolizers (PM).
Interventions:
Participants will receive a combination of probe drugs known as a CYP probe cocktail to assess baseline CYP enzyme activity. Dexamethasone will be administered, and the CYP probe cocktail will be given again to evaluate changes in enzyme activity. Voriconazole will be used to assess the potential for drug-drug interactions related to changes in CYP enzyme activity. Blood samples will be collected during the study.
Outcome Measures:
The main outcomes of this study are changes in blood concentrations of the probe drugs, which reflect changes in CYP enzyme activity, and comparisons of these changes between normal metabolizers and poor metabolizers.
Hypothesis:
The study hypothesizes that dexamethasone alters CYP enzyme activity and that the magnitude of this effect differs between normal metabolizers and poor metabolizers, potentially affecting the metabolism of drugs such as voriconazole.
The purpose of this study is to understand how dexamethasone affects the activity of drug-metabolizing enzymes in the body and how this may influence interactions with other medicines, such as voriconazole.
Background:
Many medicines are broken down in the body by enzymes called cytochrome P450 (CYP) enzymes. Differences in CYP enzyme activity between individuals can lead to variability in drug response and drug-drug interactions. Dexamethasone is known to affect CYP enzyme activity, and voriconazole is a medication that is metabolized by these enzymes.
Participants:
This study will include a total of 12 healthy adult male volunteers. Participants will be grouped based on their metabolic status, including 6 normal metabolizers (NM) and 6 poor metabolizers (PM).
Interventions:
Participants will receive a combination of probe drugs known as a CYP probe cocktail to assess baseline CYP enzyme activity. Dexamethasone will be administered, and the CYP probe cocktail will be given again to evaluate changes in enzyme activity. Voriconazole will be used to assess the potential for drug-drug interactions related to changes in CYP enzyme activity. Blood samples will be collected during the study.
Outcome Measures:
The main outcomes of this study are changes in blood concentrations of the probe drugs, which reflect changes in CYP enzyme activity, and comparisons of these changes between normal metabolizers and poor metabolizers.
Hypothesis:
The study hypothesizes that dexamethasone alters CYP enzyme activity and that the magnitude of this effect differs between normal metabolizers and poor metabolizers, potentially affecting the metabolism of drugs such as voriconazole.
开始日期2026-04-01 |
申办/合作机构- |
ChiCTR2500104674
Evaluation of the efficacy and safety of nebulized inhalation of amphotericin B deoxycholate (AmB-D) combined with azole in the treatment of invasive pulmonary mycosis in patients with hematological malignancies: A multicenter, prospective, randomized controlled study
开始日期2025-06-13 |
申办/合作机构- |
ChiCTR2500114796
Amphotericin B loaded liposomes (AmBisome ®) A prospective, open randomized, single center, superiority study on the efficacy and safety of aerosol inhalation in the treatment of chronic pulmonary aspergillosis
开始日期2025-06-01 |
申办/合作机构 |
100 项与 伏立康唑 相关的临床结果
登录后查看更多信息
100 项与 伏立康唑 相关的转化医学
登录后查看更多信息
100 项与 伏立康唑 相关的专利（医药）
登录后查看更多信息
8,313
项与 伏立康唑 相关的文献（医药）2026-12-31·ANNALS OF MEDICINE
The association between different regimens of glucocorticoid and antifungal treatment with the prognosis of allergic bronchopulmonary aspergillosis: a retrospective cohort study
Article
作者: Chen, Lei ; Jiang, Hongni ; Xu, Yiding ; Wang, Qin ; Wang, Minghui ; Wang, Sijiao ; Li, Huayin ; Zhu, Xiaodan ; Zhang, Xiaohua
BACKGROUND:
Optimal management of allergic bronchopulmonary aspergillosis (ABPA) remains debated, particularly regarding glucocorticoid (GC) dosage, duration, antifungal selection, and combination therapy. This study evaluated the impact of different regimens on ABPA prognosis.
METHODS:
A total of 76 ABPA patients at Zhongshan Hospital, Fudan University from March 2009 to June 2018 were enrolled and stratified by one-year relapse status. Demographics, treatment details (GC dosage, GC duration, antifungal type), and outcomes (GC dependence, acute exacerbations, lesion resolution, recurrence) were analyzed. Multivariate logistic regression analysis was utilized.
RESULTS:
No significant difference were observed between the relapse group (n = 20) and non-relapse group (n = 56) in baseline demographics, clinical characteristics, or use of GC duration/dosage or antifungals. The mean follow-up time for the relapse and non-relapse groups were 23.95 vs 24.91 months. The former had higher long-term GC use (>3 months) than the non-relapse group (80% vs. 30.36%, p < 0.001). Long-term GC was an independent risk factor for relapse (OR 6.85, 95%CI 1.51-31.51), GC dependence (OR 5.92, 95%CI 1.29-27.11), and acute exacerbations (OR 9.41, 95%CI 2.76-32.06). Conversely, low-dose GC (<7.5 mg/day) reduced relapse risk (OR 0.06, 95%CI 0.01-0.36), GC dependence (OR 0.07, 95%CI 0.01-0.41), and exacerbations (OR 0.16, 95%CI 0.03-0.91). Voriconazole offered superior initial efficacy vs itraconazole (OR 4.42, 95%CI 1.18-16.52) but poorer long-term lesion resolution (OR 0.24, 95%CI 0.06-0.97). Nevertheless, a higher proportion of non-relapse patients had received combination therapy compared to relapse patients (67.9% vs. 50%, p = 0.322).
CONCLUSION:
Long-term GC increases risks of adverse outcomes in ABPA, while low-dose GC demonstrates protective effects. Voriconazole provides better initial response but inferior long-term lesion resolution compared to itraconazole. More non-relapse patients on combination therapy may related to possible benefit of combination therapy. Prospective studies are warranted to confirm these findings.
2026-12-31·Journal of Pharmaceutical Policy and Practice
Comparative pharmacokinetics of voriconazole between elderly and young adult patients: a population pharmacokinetic study
Article
作者: Sattar, Adeel ; Zulfiqar, Sadaf ; Akbar, Zunaira ; Zaryab Zakria, Khawaja ; Ali, Mohsin ; Zahid Mushtaq, Muhammad ; Usman, Muhammad ; Rasheed, Huma ; Alvi, Ijaz ; Hussain, Talib ; Rehan Khan, Muhammad ; Bilal, Hajira
Background:
Voriconazole (VCZ) belongs to the class of broad-spectrum antifungal agents, and it is commonly used for the treatment of serious fungal infections. Safe and effective therapy with VCZ is a challenge due to the narrow therapeutic index and high variability in pharmacokinetics between patients. Age of the patients can be a significant factor for this variability. However, no prior study in Pakistan has compared the pharmacokinetics of VCZ among young and elderly patients.
Methods:
A population pharmacokinetic model was developed on NONMEM software by using therapeutic drug monitoring (TDM) data from 51 cancer patients. Patients were divided into two age groups, that is ≤ 65 years and > 65 years. The covariate influence on CL of VCZ was assessed by stepwise covariate modelling. The predictive performance and stability of the final model were evaluated by using goodness-of-fit plots and bootstrap analysis, respectively.
Results:
A one-compartment model with first-order elimination best described the data. The CL of VCZ in patients with age > 65 years was 3.11 L/h, which was significantly lower than the CL in patients with age ≤ 65 years, which was 6.46 L/h. No other covariate proved significant on CL and volume of distribution of VCZ. The final model demonstrated robust predictive performance and stability.
Conclusions:
The reduced CL of VCZ in elderly patients might be due to compromised hepatic enzymes in elderly patients. The dose of VCZ should be reduced in patients aged > 65 years.
2026-12-01·PARASITOLOGY RESEARCH
Multidrug-resistant Acanthamoeba keratitis caused by the T4 Genotype: A case report
Article
作者: Kazemirad, Elham ; Atighehchian, Mehrnaz ; Zarei-Ghanavati, Mehran ; Kasiri, Maryam ; Latifi, Alireza
This report describes the case of a 28-year-old woman, who presented with a two-week history of severe ocular pain and photophobia in her right eye. She was a soft contact lens wearer with no history of ocular trauma or systemic illness. Ophthalmic examination revealed conjunctival hyperemia, epithelial irregularities, and a developing ring-shaped stromal infiltrate. In vivo confocal microscopy demonstrated double-walled hyperreflective cysts, and culture followed by PCR and sequencing confirmed the presence of Acanthamoeba T4 genotype. Despite intensive treatment with topical polyhexamethylene biguanide, chlorhexidine, propamidine, and voriconazole, as well as oral miltefosine, the infection progressed, leading to stromal necrosis. The patient underwent two therapeutic penetrating keratoplasties; however, the disease continued to advance, eventually resulting in phthisis bulbi and permanent vision loss. This case highlights the potential for aggressive, clinically refractory Acanthamoeba keratitis caused by the T4 genotype, emphasizing the importance of early diagnosis, vigilant monitoring, and timely surgical intervention in resistant cases.
599
项与 伏立康唑 相关的新闻（医药）2026-02-27
报名倒计时2周，IND2026议程已公开，点击图片查看。参会咨询：李欣欣177 0186 0390。
日前，上海交通大学医学院附属瑞金医院的首批两款医疗机构自行研制体外诊断试剂成功获得上海市药品监督管理局备案，分别是维奈克拉测定试剂盒（液相色谱-串联质谱法）、利奈唑胺和伏立康唑测定试剂盒（液相色谱-串联质谱法）。
上海市药品监督管理局郭术廷副局长和上海市卫生健康委医政处余飞副处长共同向瑞金医院副院长赵维莅教授颁授备案证，上海市药品监督管理局医疗器械注册处和上海市医疗器械化妆品审评核查中心相关领导及瑞金医院自研试剂项目负责人共同见证这一重要时刻。
维奈克拉测定试剂盒（液相色谱-串联质谱法）是由国家转化医学中心（上海）印彤研究员团队自主研发，填补了我国急性髓细胞白血病（AML）治疗过程中药物浓度监测的空白，标志着AML患者的药物治疗进入个体化精准用药时代。
利奈唑胺和伏立康唑测定试剂盒（液相色谱-串联质谱法）由瑞金医院检验科团队和药剂科团队合作研发，是我国首款用于抗生素监测的医疗机构自行研制体外诊断试剂，标志着抗感染药物治疗迈入个体化精准用药新时代。
两款试剂备案过程中得到了国家卫生健康委、国家药品监督管理局、上海市药品监督管理局和上海市卫生健康委的大力支持和专业指导，上海市药品监督管理局医疗器械注册处负责同志带领上海市医疗器械化妆品审评核查中心、上海市医疗器械检验研究院和上海市临床检验中心相关专家多次到瑞金医院开展跨前指导和专题培训。
上海交通大学医学院附属瑞金医院是一所三级甲等大型综合性教学医院，是首批国家公立医院高质量发展试点医院、首批综合类国家医学中心建设单位和首批医疗机构自行研制使用体外诊断试剂试点单位，共有25项自研试剂项目入选国家药品监督管理局首批目录。作为首批上海市产医融合创新基地，瑞金医院依托国家转化医学大设施、质子中心及各学科专科研究所等，通过基础与临床的高效有机结合，打造生物医药产业乃至大健康领域的“瑞金研发”新品牌。为推进上海高端医疗器械产业高质量发展，打造更具全球影响力的高端医疗器械产业发展高地，贡献“瑞金力量”。
END
免责声明：本文仅作知识交流与分享及科普目的，不涉及商业宣传，不作为相关医疗指导或用药建议。文章如有侵权请联系删除。
报名倒计时2周，IND2026议程已公开，点击图片查看。参会咨询：李欣欣177 0186 0390。
戳“阅读原文”立即领取IND2026免费参会名额!
2026-02-26
THE LANCET Infectious Diseases. Volume 26Number 1
柳叶刀传染病学 26卷 1期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Urgent need for infection prevention and control in prisons
监狱中感染预防和控制的迫切需求
The Lancet Infectious Diseases
The Lancet Infectious Diseases Vol 26(1):p1
COMMENT（述评）
2
Now is the time to integrate serology into routine infectious disease surveillance
现在是时候将血清学纳入常规传染病监测了
Simon Cauchemez
The Lancet Infectious Diseases Vol 26(1):p2
3
Reassessing sotrovimab's role in COVID-19: insights and implications
重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示
Daniele Focosi,Fabrizio Maggi
The Lancet Infectious Diseases Vol 26(1):p3
4
Shaping opportunities for future clinical trials in tuberculosis
为未来结核病临床试验创造机会
Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich
The Lancet Infectious Diseases Vol 26(1):p5
5
Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda
乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化
Arjen M Dondorp
The Lancet Infectious Diseases Vol 26(1):p6
6
A safe start for PfSPZ Vaccine, but efficacy in children remains elusive
PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸
Nicholas Aderinto,Temitomi Jane Oyedele
The Lancet Infectious Diseases Vol 26(1):p8
7
Rifasutenizol-based triple therapy for Helicobacter pylori infection
以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染
Jinnan Chen,Hong Lu
The Lancet Infectious Diseases Vol 26(1):p9
8
The smallest faith
最渺小的信念
Steven A Pergam
The Lancet Infectious Diseases Vol 26(1):p11
9
Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease
新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标
Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson
The Lancet Infectious Diseases Vol 26(1):p13
10
Strengthening global preparedness and response to arboviral disease threats: a call to action
加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁
WHO Global Arbovirus Initiative Technical Advisory Group
世界卫生组织全球虫媒病毒倡议技术咨询小组
The Lancet Infectious Diseases Vol 26(1):p15
11
Introducing our cover artist for 2026: Daria Lada
介绍我们2026年的封面艺术家：达里亚·拉达
Marco De Ambrogi
The Lancet Infectious Diseases Vol 26(1):p17
Correspondence（读者来信）
12
Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2
新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况
Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann
The Lancet Infectious Diseases Vol 26(1):e1
13
Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation
Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响
Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens
The Lancet Infectious Diseases Vol 26(1):e3
14
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致
Nader Ebrahimi,Amir Ghaemi
The Lancet Infectious Diseases Vol 26(1):e6
15
Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply
人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复
Frank Aarestrup,Marion Koopmans
The Lancet Infectious Diseases Vol 26(1):e7
16
Time to tackle vaccine–HLA associations with artificial intelligence
是时候用人工智能解决疫苗-人类白细胞抗原关联问题了
Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington
The Lancet Infectious Diseases Vol 26(1):e8
Corrections（更正）
17
Correction to Lancet Infect Dis 2025; published online Oct 29.
《柳叶刀-传染病》2025年更正；在线发表于10月29日
https://doi.org/10.1016/S1473-3099(25)00466-9
The Lancet Infectious Diseases Vol 26(1):e9
18
Correction to Lancet Infect Dis 2025; published online Oct 27.
《柳叶刀-传染病》2025年更正；在线发表于10月27日
https://doi.org/10.1016/S1473-3099(25)00546-8
The Lancet Infectious Diseases Vol 26(1):e9
19
Correction to Lancet Infect Dis 2025; 25: 1084–96
《柳叶刀-传染病》2025年更正；25卷：1084-1096页
The Lancet Infectious Diseases Vol 26(1):e9
20
Correction to Lancet Infect Dis 2025; published online Nov 10.
《柳叶刀-传染病》2025年更正；在线发表于11月10日
https://doi.org/10.1016/S1473-3099(25)00550-X
The Lancet Infectious Diseases Vol 26(1):e9
Newsdesk（新闻台）
21
Highlights of IDWeek 2025
2025年IDWeek亮点
Phoebe Hall
The Lancet Infectious Diseases Vol 26(1):e10
22
WHO publishes update on global antibiotic resistance
世界卫生组织发布全球抗生素耐药性最新情况
Timothy Jesudason
The Lancet Infectious Diseases Vol 26(1):e11
23
European Commission to fund new medicines for dengue
欧盟委员会资助登革热新药研发
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):e12
24
Second report from the UK Covid-19 Inquiry
英国新冠肺炎调查第二次报告
Talha Burki
The Lancet Infectious Diseases Vol 26(1):e13
25
Infectious disease surveillance update
传染病监测最新情况
Cahal McQuillan
The Lancet Infectious Diseases Vol 26(1):e14
26
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases Vol 26(1):e15
Obituary（讣告）
27
Jean Louis Abdourahim Ndiaye
让·路易斯·阿卜杜拉希姆·恩迪亚耶
Sanjeet Bagcchi
The Lancet Infectious Diseases Vol 26(1):p19
Profile（人物介绍）
28
Fortunate Machingura—tackling climate change and disease
福图纳特·马辛古拉——应对气候变化与疾病
Tony Kirby
The Lancet Infectious Diseases Vol 26(1):p20
Media Watch（媒体观察）
Book（书籍）
29
The social and political drivers behind pandemics
大流行背后的社会和政治驱动因素
Emma Louise Fabiani
The Lancet Infectious Diseases Vol 26(1):p21
Articles（论著）
30
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study
新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究
Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek
The Lancet Infectious Diseases Vol 26(1):p22
31
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验
RECOVERY Collaborative Group
RECOVERY协作组
The Lancet Infectious Diseases Vol 26(1):p34
32
A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial
含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验
John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team
The Lancet Infectious Diseases Vol 26(1):p46
33
Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories
2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析
Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar
The Lancet Infectious Diseases Vol 26(1):p55
34
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial
乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验
Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka
The Lancet Infectious Diseases Vol 26(1):p67
35
Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial
加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验
Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller
The Lancet Infectious Diseases Vol 26(1):p79
36
Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study
TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究
Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda
The Lancet Infectious Diseases Vol 26(1):p91
37
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial
以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验
Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group
The Lancet Infectious Diseases Vol 26(1):p101
Series（专题研讨会）
38
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Innovation in active and passive immunisation of people who are immunocompromised: a call to action
免疫功能低下人群主动和被动免疫接种的创新：行动呼吁
Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa
The Lancet Infectious Diseases Vol 26(1):e16
39
Prevention and Management of Infections in People who are Immunocompromised
免疫功能低下人群感染的预防和治疗
Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship
应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理
Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo
The Lancet Infectious Diseases Vol 26(1):e30
Review（综述）
40
Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project
揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述
Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro
The Lancet Infectious Diseases Vol 26(1):e49
Personal View（个人观点）
41
Azithromycin mass drug administration: balancing survival benefits and risks in children
阿奇霉素大规模药物给药：平衡儿童生存益处与风险
Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro
The Lancet Infectious Diseases Vol 26(1):e62
Clinical Picture（临床影像）
42
Unexpected finding in a 17-year-old female undergoing screening colonoscopy
17岁女性接受筛查结肠镜检查时的意外发现
Ziheng Calvin Xu,Ethan Tan,Mayur Garg
The Lancet Infectious Diseases Vol 26(1):e75
THE LANCET Infectious Diseases. Volume 26Number 2
柳叶刀传染病学 26卷 2期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL(社论)
1
Call for letters
征稿启事
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111
Comment（述评）
2
Long COVID is here to stay—even in children
长期新冠症状将持续存在——即使在儿童中亦是如此
Danilo Buonsenso
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112
3
Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment
利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用
Ming Hong Choi,Ivan Fan Ngai Hung
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113
4
A new monoclonal in the arMAMentarium against malaria
抗疟“武器库”中的新型单克隆抗体
Freia-Raphaella Lorenz,Matthew B B McCall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115
5
Household transmission of mpox in Africa: limited in adults but more prevalent in children
非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍
Oriol Mitjà,Michael Marks
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117
6
The lasting lessons of mpox: infection, vaccination, and immune memory
猴痘带来的持久教训：感染、疫苗接种和免疫记忆
Raianna Fantin,Camila H Coelho
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118
7
Xpert-Ultra for diagnosing asymptomatic tuberculosis
Xpert-Ultra用于诊断无症状结核病
Xia Yu,Hairong Huang
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120
8
The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action
基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动
David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122
Correspondence（读者来信）
9
Spillover in dengue trials
登革热试验中的溢出效应
Thomas A Smith,Samuel I Watson
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77
10
Spillover in dengue trials – Author's reply
登革热试验中的溢出效应——作者回复
Fernando Abad-Franch
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78
11
Updating the traditional voriconazole trough concentration range
传统的伏立康唑谷浓度范围更新
Rongqiang Liao,Xiaoyuan Zheng
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79
12
Updating the traditional voriconazole trough concentration range – Authors' reply
传统的伏立康唑谷浓度范围更新——作者回复
Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80
13
Clinical course and neurological profile of Kyasanur Forest disease
基萨努尔森林病的临床病程和神经特征
Nitin Gupta,Tirlangi Praveen Kumar
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82
Corrections（更正）
14
Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7
对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
15
Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4
对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83
Newsdesk（新闻台）
16
Promising early data for sorfequiline
索氟维林早期数据令人鼓舞
Ed Holt
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84
17
Highlights from ASTMH 2025
2025年美国热带医学与卫生学会年会亮点
Marco De Ambrogi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85
18
Brazil approves domestic single-shot dengue vaccine
巴西批准国产单剂登革热疫苗
Marcia Triunfol
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86
19
CDC cuts to childhood vaccine recommendations
美国疾控中心削减儿童疫苗接种建议
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87
20
WHO launches unified plan for coronaviruses
世界卫生组织启动冠状病毒统一计划
Talha Burki
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88
21
Infectious disease surveillance update
传染病监测更新
Cahal McQuillan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89
22
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90
Obituary（讣告）
23
Walter Dowdle
沃尔特·道德尔
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124
Profile（人物简介）
24
Katie Anders—improving global dengue control
凯蒂·安德斯——改善全球登革热防控
Tony Kirby
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125
Media Watch（媒体观察）
Film（电影）
25
Eliminating Guinea worm
根除麦地那龙线虫
Sanjeet Bagcchi
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126
Articles（论著）
26
Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study
奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127
27
Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验
William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139
28
Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial
头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验
David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148
29
Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验
single-blind, randomised, controlled, dose-ranging, phase 2 trial
Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160
30
Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial
人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验
Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170
31
Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study
布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究
Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182
32
Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study
比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究
Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190
33
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study
乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究
Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203
Review（综述）
34
Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge
侵袭性A组链球菌感染：从2022-23年激增中吸取的教训
Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91
35
A clinical practice guideline for tuberculous meningitis
结核性脑膜炎临床实践指南
Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96
36
Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults
缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症
Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112
Personal View（个人观点）
37
A transformation in cholera surveillance
霍乱监测的变革
Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124
Clinical Picture（临床图像）
38
Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing
尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展
Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel
The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130
THE LANCET Infectious Diseases. Volume 26Number 3
柳叶刀传染病学 26卷 3期
https://www.thelancet.com/journals/laninf/issue/current
EDITORIAL（社论）
1
Promises and challenges of AI in infectious diseases
人工智能在传染病领域的承诺与挑战
The Lancet Infectious Diseases
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213
COMMENT（述评）
2
More real-world evidence for RSV vaccines in the global community
全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据
Kristina L Bajema,Wesley H Self
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214
3
Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet
猴痘快速诊断抗原检测及分散检测的必要性——尚待完善
Daniel Mukadi-Bamuleka,Kevin K Ariën
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215
4
Solving the data bottleneck for artificial intelligence in infectious diseases
解决传染病人工智能领域的数据瓶颈问题
Cesar de la Fuente-Nunez
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217
5
Artificial intelligence and One Health: potential for spillover prediction?
人工智能与“同一健康”理念：能否预测病原体外溢？
Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219
6
Artificial intelligence in the development of vaccines for infectious diseases
人工智能在传染病疫苗研发中的应用
Steve Black,Shabir A Madhi,Rino Rappuoli
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221
7
Peer review at The Lancet Infectious Diseases in 2025
2025年《柳叶刀-传染病学》期刊专家评审
Ursula Hofer
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223
8
Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025
感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家
The Lancet Infectious Diseases Editors
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132
CORRESPONDENCE（读者来信）
9
Methodological considerations in the attribution of long COVID to first or second infection
首次或二次感染导致长期新冠症状的方法学考量
Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139
10
Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply
首次或二次感染导致长期新冠症状的方法学考量——作者回复
Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141
11
Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2
LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答
Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142
12
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者
Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144
13
Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply
金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复
David L Paterson,Abdullah T Aslan,Patrick N A Harris
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145
CORRECTIONS（更正）
14
Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0
《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
15
Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X
《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146
NEWSDESK（新闻台）
16
Rabies an increasing threat in Ukraine
乌克兰狂犬病威胁日益加剧
Ed Holt
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147
17
People needing trachoma interventions at record low
需要沙眼干预措施的人数创历史新低
Timothy Jesudason
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148
18
Uneven STI response in EU/EEA countries
欧盟/欧洲经济区国家性传播感染应对措施不均衡
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149
19
Controversial HBV vaccine trial in Guinea-Bissau halted
几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停
Talha Burki
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150
20
Research in brief
研究简讯
Priya Venkatesan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151
OBITUARY（讣告）
21
Ivan Hirsch
伊万·赫希
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224
PROFILE（人物介绍）
22
Reem Abu Shomar— championing water safety in Gaza
里姆·阿布·舒马尔——加沙地带水安全倡导者
Tony Kirby
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225
MEDIA WATCH（媒体观察）
Book（书籍）
23
A prescription for public health literacy
提升公众健康素养的良方
Vijay Shankar Balakrishnan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226
Book（书籍）
24
Imagining the inevitable
想象不可避免之事
Cahal McQuillan
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227
Film（电影）
25
Women's autonomy, safe sex and HIV prevention
女性自主权、安全性行为与艾滋病预防
Sanjeet Bagcchi
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228
ARTICLES（论著）
26
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study
英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究
Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229
27
Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial
印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验
Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239
28
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析
Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250
29
Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study
刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究
Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260
30
Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis
伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析
Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270
31
Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析
GBD 2023 Chagas Disease and RAISE Study Collaborators
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284
32
Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial
乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验
Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302
33
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial
美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验
Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314
SERIES（研讨会）
Artificial Intelligence and Infectious Diseases
人工智能与传染病
34
Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice
人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架
Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152
35
Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives
人工智能与传染病诊断：现状与未来展望
Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168
36
Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery
人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现
Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181
REVIEW（综述）
37
Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia
血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议
Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193
CLINICAL PICTURE（临床图像）
38
Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection
人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染
Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B
Spiller,Baharak Afshar
The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207
疫苗信使RNA临床1期临床研究
2026-02-25
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled out to support accelerated market penetration and expanded reach
Focused on unlocking the full market potential of Talicia, the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1, THI and Cumberland will manage the launch and ongoing joint commercialization activities
H. pylori infection affects 35% of the U.S. adult population and an estimated 1.6 million U.S. patients are treated annually2. Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based H. pylori therapy addressing antibiotic resistance and is recommended as an empiric first-line H. pylori therapy in the American College of Gastroenterology (ACG) Clinical Guideline3
RALEIGH, N.C. and TEL-AVIV, Israel, Feb. 25, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. ("THI") and Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), has started and is now being rolled out to support accelerated market penetration and expanded reach. This marks the operational launch of the joint commercialization model previously announced in October 2025, including Cumberland's $4 million strategic investment.
Focused on unlocking the full market potential of Talicia, the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy, THI, a RedHill and Cumberland jointly controlled operating entity (70/30 RedHill/ Cumberland ownership) will manage the launch and ongoing joint commercialization, in coordination with Cumberland.
"H. pylori infection affects 35% of the U.S. adult population and is a leading cause of gastric cancer, responsible for approximately 11,000 related U.S. deaths a year,"
said Rick Scruggs, President of THI and RedHill's Chief Commercial Officer. "Patients should have access to the most effective, clinically differentiated, therapies designed to eradicate H. pylori infection on the first attempt, while mitigating the risk of antibiotic resistance. We are excited to propel Talicia into its next phase of growth in this expanding market. We are integrating key commercial resources and leveraging our combined expertise to balance stronger prescription growth with the delivery of operational efficiencies as we drive to ensure that more patients benefit from this important therapy."
Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based H. pylori therapy designed to address growing antibiotic resistance concerns to other available therapies. It is listed as a first-line H. pylori treatment option in the 2024 American College of Gastroenterology (ACG) Clinical Guideline, which emphasizes using 14-day, "optimized" regimens for the first attempt to maximize cure rates and avoid the need for complex, less-effective salvage therapies4. It is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation. Talicia is also the only FDA-approved medication for H. pylori infection with an all-in-one formulation, with the added benefit of simple dosing.
RedHill continues to work towards expanding patient access to Talicia globally. Efforts focused on potential new market entries in the UK and the Middle East, along with work to further broaden market access and secure additional non-dilutive ex-U.S. licensing revenue streams, are ongoing.
About H. pylori
H. pylori is a bacterial infection that affects approximately 35% of the U.S. adult population (an estimated 1.6 million U.S. patients are treated annually) rising to more than 50% globally[4]. Classified by the World Health Organization (WHO) as a Group 1 carcinogen, H. pylori is the strongest known risk factor for gastric cancer (between 70% to 90% of cases with more than 27,000 Americans diagnosed with gastric cancer annually5 and approximately 800,000 deaths globally per year), a major risk factor for peptic ulcer disease (90% of cases)6 and gastric mucosa-associated lymphoid tissue (MALT) lymphoma7. Eradication of H. pylori is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients who remain H. pylori-positive due to high resistance of H. pylori to antibiotics, especially clarithromycin, which is still commonly used in standard combination therapies8.
About Talicia®
Approved by the FDA for the treatment of H. pylori infection in adults in November 2019, Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole). Talicia received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents extending patent protection through 2042 with additional patents and applications pending and granted in various territories worldwide. Talicia is also approved by the United Arab Emirates (UAE) Ministry of Health.
About RedHill Biopharma
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal drug
Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults9, with a recent co-commercialization agreement in the U.S. with Cumberland Pharmaceuticals. RedHill's key clinical late-stage development programs include: (i)
opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, and anticancer activity, targeting multiple indications with U.S. government and academic collaborations for development for medical countermeasures including radiation and chemical exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 study in prostate cancer in combination with darolutamide; (ii)
RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results); (iii)
RHB-102, with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America; and (iv)
RHB-107 (
upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases.
More information about the Company is available at / X.com/RedHillBio.
TALICIA: INDICATION AND IMPORTANT SAFETY INFORMATION
Talicia is a three-drug combination of omeprazole, a proton pump inhibitor, amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial, indicated for the treatment of Helicobacter pylori infection in adults.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
Talicia contains omeprazole, a proton pump inhibitor (PPI), amoxicillin, a penicillin-class antibacterial and rifabutin, a rifamycin antibacterial. It is contraindicated in patients with known hypersensitivity to any of these medications, any other components of the formulation, any other beta-lactams or any other rifamycin.
Talicia is contraindicated in patients receiving rilpivirine-containing products.
Talicia is contraindicated in patients receiving delavirdine or voriconazole.
Serious and occasionally fatal hypersensitivity reactions have been reported with omeprazole, amoxicillin and rifabutin.
Drug-induced enterocolitis syndrome (DIES) has been reported with use of amoxicillin, a component of Talicia.
Severe cutaneous adverse reactions (SCAR) (e.g., Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN)) have been reported with rifabutin, amoxicillin, and omeprazole. Additionally, drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported with rifabutin.
Acute Tubulointerstitial Nephritis has been observed in patients taking PPIs and penicillins.
Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range from mild diarrhea to fatal colitis.
Talicia may cause fetal harm. Talicia is not recommended for use in pregnancy. Talicia may reduce the efficacy of hormonal contraceptives. An additional non-hormonal method of contraception is recommended when taking Talicia.
Talicia should not be used in patients with hepatic impairment or severe renal impairment.
Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. These events have occurred as both new onset and exacerbation of existing autoimmune disease.
The most common adverse reactions (≥1%) were diarrhea, headache, nausea, abdominal pain, chromaturia, rash, dyspepsia, oropharyngeal pain, vomiting, and vulvovaginal candidiasis.
To report SUSPECTED ADVERSE REACTIONS, contact RedHill Biopharma INC. at
1-833-ADRHILL (1-833-237-4455) or FDA at 1-800-FDA-1088 or .
Full prescribing information for Talicia is available at .
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words, and include, among others, statements regarding the potential impact of the relationship with Cumberland on the commercialization of Talicia. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that co-commercialization of Talicia with Cumberland may not provide the anticipated commercial and operational benefits to RedHill's global Talicia business or to RedHill's financial position, costs or its broader strategic objectives, including accelerating prescriptions, improving operational efficiencies and enabling more patients to benefit from Talicia; the risk regarding the Company's ability to maintain compliance with Nasdaq's listing requirements, including the minimum stockholders' equity requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia®; (v) the Company's ability to successfully commercialize and promote Talicia®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 10, 2025. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.
Category: Corporate
[1] IQVIA XPO Data on file
[2] Hooi JKY et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153:420-429.
[3] Chey W, Howden C, Moss S, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;119:1730-53.
[4] Hooi JKY et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153:420-429.
[5] National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER).
[6] Malfertheiner, P., Camargo, M.C., El-Omar, E. et al. Helicobacter pylori infection. Nat Rev Dis Primers 9, 19 (2023).
[7] Hu Q et al. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management. Biomarker research 2016;4.1:15.
[8] Malfertheiner P. et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report, Gut 2012;61:646-664; O'Connor A. et al. Treatment of Helicobacter pylori Infection 2015, Helicobacter 20 (S1) 54-61; Venerito M. et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013;88(1):33-45.
[9] Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: .
Logo -
SOURCE RedHill Biopharma Ltd.
21%
more press release views with
Request a Demo
临床结果临床2期临床3期引进/卖出上市批准
100 项与 伏立康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 侵袭性念珠菌病 | 欧盟 | 2013-05-16 | |
| 侵袭性念珠菌病 | 冰岛 | 2013-05-16 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2013-05-16 | |
| 侵袭性念珠菌病 | 挪威 | 2013-05-16 | |
| 茎孢子虫病 | 美国 | 2003-12-19 | |
| 系统性念珠菌病 | 澳大利亚 | 2002-09-03 | |
| 镰刀菌病 | 美国 | 2002-05-24 | |
| 念珠菌血症 | 欧盟 | 2002-03-19 | |
| 念珠菌血症 | 冰岛 | 2002-03-19 | |
| 念珠菌血症 | 列支敦士登 | 2002-03-19 | |
| 念珠菌血症 | 挪威 | 2002-03-19 | |
| 念珠菌病 | 欧盟 | 2002-03-19 | |
| 念珠菌病 | 冰岛 | 2002-03-19 | |
| 念珠菌病 | 列支敦士登 | 2002-03-19 | |
| 念珠菌病 | 挪威 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 欧盟 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 冰岛 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 列支敦士登 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 挪威 | 2002-03-19 | |
| 侵袭性真菌感染 | 欧盟 | 2002-03-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白血病 | 临床3期 | 美国 | 2009-05-01 | |
| 肺曲霉菌病 | 临床3期 | 法国 | 2005-07-01 | |
| 发热 | 临床3期 | 德国 | 2005-01-01 | |
| 真菌性角膜炎 | 临床2期 | 中国 | 2025-01-16 | |
| 侵袭性肺曲霉菌病 | 临床2期 | 丹麦 | 2022-08-02 | |
| 腔内曲霉菌球 | 临床2期 | 日本 | 2011-09-01 | |
| 全身性真菌病 | 临床2期 | 美国 | 2008-06-01 | |
| 中性粒细胞减少 | 临床2期 | - | 2003-06-01 | |
| 哮喘 | 临床1期 | 澳大利亚 | 2020-11-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2/3期 | 94 | 襯衊醖獵衊衊衊膚遞鹽(鑰鹹糧積鹹築願窪繭構) = 顧觸壓選蓋繭淵糧觸鬱 醖顧壓壓鹹遞廠憲窪蓋 (襯鏇鹹窪鹹鑰範醖壓廠 ) 更多 | 不佳 | 2025-12-09 | |||
Natamycin 5% plus Placebo | 襯衊醖獵衊衊衊膚遞鹽(鑰鹹糧積鹹築願窪繭構) = 鏇餘鏇壓選築網蓋醖觸 醖顧壓壓鹹遞廠憲窪蓋 (襯鏇鹹窪鹹鑰範醖壓廠 ) 更多 | ||||||
N/A | 8,068 | 鬱衊齋築網餘選膚艱壓(繭艱觸蓋顧願衊繭構鑰) = 醖鹹範範網願選糧築構 鹽艱製鏇窪繭夢廠獵範 (醖積壓獵糧觸鏇襯鏇鏇 ) 更多 | 积极 | 2025-12-06 | |||
鬱衊齋築網餘選膚艱壓(繭艱觸蓋顧願衊繭構鑰) = 鹽壓製簾獵鬱願窪衊醖 鹽艱製鏇窪繭夢廠獵範 (醖積壓獵糧觸鏇襯鏇鏇 ) 更多 | |||||||
临床3期 | 116 | 鹽範鏇憲鏇鏇憲鑰構淵(淵糧鬱衊繭蓋夢淵鏇壓) = 獵鑰憲製構繭憲鹽艱範 觸齋積夢齋範餘窪蓋選 (積廠鏇網顧艱鹽遞鏇簾 ) 更多 | 不佳 | 2025-10-01 | |||
鹽範鏇憲鏇鏇憲鑰構淵(淵糧鬱衊繭蓋夢淵鏇壓) = 壓選衊齋製願鏇蓋鹽夢 觸齋積夢齋範餘窪蓋選 (積廠鏇網顧艱鹽遞鏇簾 ) 更多 | |||||||
临床1期 | 15 | 鑰範鏇餘鏇選簾觸簾鹽(齋醖獵網淵構夢製壓選) = 艱醖衊壓鏇鏇艱衊窪觸 壓糧願夢鏇繭夢窪糧醖 (鏇艱襯遞餘壓願衊襯製 ) 更多 | 积极 | 2025-09-15 | |||
临床2期 | 10 | 齋憲積願膚憲鹹繭鹹艱 = 鏇淵鹹憲繭壓醖廠醖廠 鏇糧繭獵艱襯遞艱鹽糧 (鹽淵廠鹽繭選糧餘鏇膚, 選艱憲憲餘鑰壓鬱艱願 ~ 觸醖鏇鏇構夢壓窪製淵) 更多 | - | 2025-01-22 | |||
N/A | 20 | 齋淵蓋蓋選鏇網網艱艱(廠憲衊範壓積壓範鏇壓) = 範網憲顧鬱齋壓鏇廠齋 艱壓膚淵淵鏇鏇膚網鹹 (壓鹽壓齋糧獵範齋膚膚 ) 更多 | 不佳 | 2024-05-14 | |||
临床2期 | 9 | 選壓鏇鏇繭鹹觸餘齋夢(鹽齋襯衊獵鏇蓋簾製蓋) = 遞網繭獵餘膚觸襯築積 構鹹衊鹹憲鑰壓選簾窪 (憲鏇製築衊醖淵衊鹽繭 ) 更多 | 积极 | 2023-12-19 | |||
- | |||||||
临床1期 | - | 17 | Microdosed midazolam | 醖鬱遞餘築鏇範膚範鹽(糧醖窪夢艱範選製範齋) = 窪餘觸廠構積憲獵襯鏇 鬱觸餘鬱鏇齋憲選製壓 (壓膚齋鬱窪餘範築醖簾 ) | - | 2023-07-28 | |
临床1期 | - | 48 | 顧襯蓋蓋築製選鬱襯憲(願淵憲壓築壓簾夢願鹽) = 築鑰壓憲遞遞糧糧製鹹 顧艱繭鏇網鑰夢膚齋糧 (願廠醖遞觸構廠繭糧鏇 ) 更多 | - | 2023-03-03 | ||
顧襯蓋蓋築製選鬱襯憲(願淵憲壓築壓簾夢願鹽) = 夢鏇鏇窪觸壓構構鬱鏇 顧艱繭鏇網鑰夢膚齋糧 (願廠醖遞觸構廠繭糧鏇 ) 更多 | |||||||
临床3期 | 85 | 鏇糧築築窪獵壓簾簾淵(獵鹽顧醖蓋積壓糧鬱糧) = 繭鏇觸鹹遞顧遞艱鏇餘 糧鹹膚築壓夢願鬱網蓋 (鹽繭簾醖積餘醖獵鏇選 ) 更多 | 积极 | 2023-03-01 | |||
鏇糧築築窪獵壓簾簾淵(獵鹽顧醖蓋積壓糧鬱糧) = 築鹹顧壓襯襯壓襯網觸 糧鹹膚築壓夢願鬱網蓋 (鹽繭簾醖積餘醖獵鏇選 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用